Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
19.50
-1.58 (-7.50%)
At close: Mar 18, 2026, 4:00 PM EDT
19.89
+0.39 (2.00%)
After-hours: Mar 18, 2026, 5:57 PM EDT
Neurogene Revenue
In the year 2024, Neurogene had annual revenue of $925.00K.
Revenue (ttm)
$925.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
107
Market Cap
302.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNGNE News
- 7 days ago - Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Business Wire
- 15 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 5 weeks ago - Neurogene to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Business Wire
- 2 months ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha